PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference

November 30, 2021 13:09:51

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received authorization from the U.S. Food and Drug Administration (“FDA”) for an investigator-initiated, randomized, placebo-controlled phase 2 clinical trial; the trial is designed to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The company noted that the primary investigator for the trial, Dr. Anthony Back, received an investigational new drug (“IND”) approval letter from the FDA, authorizing the trial. In addition, the study has received Institutional Review Board (“IRB”) approval at the University of Washington. Cybin also announced that CEO Doug Drysdale will be an active participant in the upcoming second annual H.C. Wainwright Psychedelics Conference. The virtual event is scheduled for Dec. 6, 2021. Drysdale will be part of a fireside chat, slated to start at 7 a.m. ET. Drysdale’s presentation will be available on demand; an archived version of the event will be available on the company’s investor relations website. “This clinical trial provides an opportunity to better understand the effectiveness of combining psilocybin and EMBARK,” said Cybin CEO Doug Drysdale in the press release announcing the phase 2 trial approvals. “Learnings from this combination Phase 2 trial will inform the use of EMBARK in Cybin’s upcoming human studies using CYB003, a proprietary deuterated psilocybin analog that has the potential to reduce clinic times and dosing levels in half as well as potentially reduce side effects and adverse events.”

To view the fireside chat, visit

To view the full press releases, visit and

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.